01991nas a2200421   4500000000100000008004100001260001300042653002500055653001000080653002900090653001100119653001100130653001100141653002500152653001900177653001900196653001800215653002400233653002500257653000900282653001600291653001700307653000900324653001700333100001500350700002200365700001400387700001100401700001300412700001500425700001600440245013800456856004100594300001000635490000700645520090300652022001401555       2004                            d  c2004 Mar10aAdministration, Oral10aAdult10aAnti-Inflammatory Agents10aBiopsy10aFemale10aHumans10aImmunohistochemistry10aInterleukin-1010aInterleukin-1310aInterleukin-610aLeprosy, Borderline10aLeprosy, lepromatous10aMale10aMiddle Aged10aPrednisolone10aSkin10aTime Factors1 aAtkinson S1 aKhanolkar-Young S1 aMarlowe S1 aJain S1 aReddy RG1 aSuneetha S1 aLockwood DN00aDetection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 (T1R) reactions.  uhttp://ila.ilsl.br/pdfs/v72n1a04.pdf  a27-340 v723 a<p>This study demonstrates the presence of IL-10 and IL-6, by immunohistochemistry, in the skin lesions of patients with Type 1 reactions. Fifteen patients with Type 1 reaction from Hyderabad, India were included in this study. They were all receiving standardized treatment for Type 1 reactions: a reducing course of daily oral prednisolone for 6 months. Biopsies were taken before treatment and during treatment at weeks 1, 4, and 6 months. IL-13 was observed in the lesions of most patients. By week 4 of treatment, the presence of IL-13, IL-10, and IL-6 in the lesions had decreased significantly. Although some patients showed significant clinical skin sign improvement within one week of therapy, no concomitant decrease or increase in any of the cytokines was observed at this time point. Interestingly, some cytokine activity within the lesions was observed after 6 months of treatment.</p>  a0148-916X